Becton Dickinson Q4 2026 earnings

BDX · 2026-11-05 06:31 BMO ET · 8-K on SEC

Revenue grew 5% year-over-year, but adjusted EPS declined 2% due to a 1.2 percentage-point compression in adjusted EBITDA margin.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$10.26B+5%+2%Ex. 99.1, Income Statement
EPS (GAAP)$1.85+2%+1%Ex. 99.1, Income Statement
EPS (adjusted)$2.20-2%+1%Ex. 99.1, Income Statement
Net income$1.30B+3%+2%Ex. 99.1, Income Statement
Adj. EBITDA$2.44B+2%+1%Ex. 99.1, Income Statement
Adj. EBITDA margin23.8%-1.2 pp+0.3 ppEx. 99.1, Income Statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
Medical - Surgical$3.20B+4%31%Strong performance in U.S. and international markets
Interventional$2.10B+6%20%Solid growth in catheters and guidewires
Diabetes Care$2.50B+3%24%Steady demand for insulin delivery systems
MedTech$2.46B+7%24%Growth in respiratory and vascular products

Margins and costs

  • Gross margin 67.6% (prior 67.8%, change -0.2 pp)
  • Operating expenses $3.04B (+4% YoY)
  • One-offs in the quarter Tax rate impact: 16.5% (vs 18.0% prior year); Restructuring charges: $8M
  • Effective tax rate 16.5% (prior-year 18.0%, year-to-date 17.2%)
  • Non-GAAP bridge Adds back stock-based compensation ($312M), amortization of intangibles ($115M), and acquisition-related costs ($45M).

KPIs

MetricActualPrior quarterPrior yearChange
Free cash flow$1.85B$1.70B$1.80B+9%
Revenue backlog$12.5B$12.0B$11.8B+4%

Guidance

MetricGuidePrior guideChange
Revenue$10.5B - $10.7B$10.4B - $10.6B+0.1 pp
Adjusted EPS$2.15 - $2.25$2.20 - $2.30-0.05 pp

What drove it

  • Revenue story Revenue increased 5% year-over-year, driven by strength in MedTech (+7%) and Interventional (+6%), partially offset by a 3% decline in Diabetes Care.
  • EPS story Adjusted EPS declined 2% year-over-year, primarily due to a 1.2 percentage-point compression in adjusted EBITDA margin and higher operating expenses (+4%).
  • One-off check Restructuring charges of $8M and a lower tax rate of 16.5% (vs 18.0% prior year) impacted the quarter.

The good

  • Revenue backlog grew 4% to $12.5B
  • Free cash flow increased 9% to $1.85B

The bad

  • Adjusted EPS declined 2% year-over-year
  • Adjusted EBITDA margin compressed 1.2 pp

The ugly

  • none

Open questions

  • The release does not quantify the specific impact of the lower tax rate on net income.
  • The release does not disclose the specific drivers of the 3% decline in Diabetes Care revenue.
Full release

Becton Dickinson (BDX) earnings release, November 5, 2026

Becton Dickinson & Co (BDX) · Form 8-K, Item 2.02 · Filed · SEC filing

Attachments

Seq Document Description

───────────────────────────────────────────────────────────────────────────────

2 ex9919302026.htm Additional exhibits

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Becton Dickinson earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.